Paediatric and adult bronchiectasis: Vaccination in prevention and management

• Published in: Respirology (Carlton, Vic.) Vol. 24; no. 2; pp. 107 - 114
• Main Authors: O'Grady, Kerry‐Ann F., Cripps, Allan W., Grimwood, Keith
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01-02-2019; Wiley Subscription Services, Inc
• Subjects: Adult; adults; Asthma; Bronchiectasis; Bronchiectasis - complications; Bronchiectasis - therapy; Child; Children; Cystic fibrosis; Disease Progression; Humans; Influenza; Lung diseases; Needs Assessment; Obstructive lung disease; Pertussis; Protein D; Respiratory function; Respiratory Tract Infections - etiology; Respiratory Tract Infections - microbiology; Respiratory Tract Infections - prevention & control; Streptococcus infections; Tuberculosis; Vaccination - methods; Vaccine development; Vaccines; Vaccines - classification; Vaccines - pharmacology; children; vaccines; bronchiectasis; adults
• ISSN: 1323-7799; 1440-1843
• DOI: 10.1111/resp.13446

ABSTRACT
Bronchiectasis has received increased attention recently, including an emphasis on preventing infective exacerbations that are associated with disease progression and lung function decline. While there are several bacteria and viruses associated with bronchiectasis, licensed vaccines are only currently available for Streptococcus pneumoniae, Haemophilus influenzae (H. influenzae protein D as a conjugate in a pneumococcal vaccine), Mycobacterium tuberculosis, Bordetella pertussis and influenza virus. The evidence for the efficacy and effectiveness of these vaccines in both preventing and managing bronchiectasis in children and adults is limited with the focus of most research being on other chronic lung disorders, such as chronic obstructive pulmonary diseases, asthma and cystic fibrosis. We review the existing evidence for these vaccines in bronchiectasis and highlight the existing gaps in knowledge. High‐quality experimental and non‐experimental studies using current state‐of‐the‐art microbiological methods and validated, standardised case definitions are needed across the depth and breadth of the vaccine development pathway.